Cargando…

In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016

BACKGROUND: Ceftolozane-tazobactam (C/T) is a novel β-lactam β-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of C/T and relevant comparators vs. a large collection of antimicrobi...

Descripción completa

Detalles Bibliográficos
Autores principales: Walkty, Andrew, Adam, Heather J, Baxter, Melanie, Lagace-Wiens, Philippe, Karlowsky, James, Hoban, Daryl, Zhanel, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630865/
http://dx.doi.org/10.1093/ofid/ofx163.913
_version_ 1783269311799885824
author Walkty, Andrew
Adam, Heather J
Baxter, Melanie
Lagace-Wiens, Philippe
Karlowsky, James
Hoban, Daryl
Zhanel, George
author_facet Walkty, Andrew
Adam, Heather J
Baxter, Melanie
Lagace-Wiens, Philippe
Karlowsky, James
Hoban, Daryl
Zhanel, George
author_sort Walkty, Andrew
collection PubMed
description BACKGROUND: Ceftolozane-tazobactam (C/T) is a novel β-lactam β-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of C/T and relevant comparators vs. a large collection of antimicrobial non-susceptible (NS) P. aeruginosa clinical isolates obtained from patients across Canada (CANWARD, 2008–2016). METHODS: From January 2008 to December 2016, inclusive, 12 to 15 sentinel hospitals across Canada submitted clinical isolates from patients attending ERs, medical and surgical wards, hospital clinics, and ICUs (CANWARD). Each center was asked to annually submit clinical isolates (consecutive, one per patient/infection site) from blood, respiratory, urine, and wound infections. Susceptibility testing was performed using broth microdilution as described by CLSI. Multidrug-resistant (MDR) P. aeruginosa were defined as isolates that tested NS to at least one antimicrobial from ≥3 classes. Extensively drug-resistant (XDR) P. aeruginosa were defined as isolates that tested NS to at least one antimicrobial from ≥5 classes. RESULTS: 3229 P. aeruginosa isolates were obtained as a part of CANWARD. The in vitro activity of C/T and relevant comparators is presented below. CONCLUSION: C/T demonstrated excellent in vitro activity vs. antimicrobial NS P. aeruginosa clinical isolates, including MDR, XDR, and meropenem NS subsets. It may prove useful in the treatment of infections caused by these organisms. DISCLOSURES: D. Hoban, Abbott: Research relationship, Research support Achaogen: Research relationship, Research support Astellas: Research relationship, Research support Merck Canada: Research relationship, Research support Merck USA: Research relationship, Research support Paratek Pharma: Research relationship, Research support Pharmascience: Research relationship, Research support Sunovion: Research relationship, Research support Tetraphase: Research relationship, Research support The Medicines Co.: Research relationship, Research support Zoetis: Research relationship, Research support; G. Zhanel, Achaogen: Research relationship, Research support Astellas: Research relationship, Research support Merck Canada: Research relationship, Research support Merck USA: Research relationship, Research support Paratek Pharma: Research relationship, Research support Pharmascience: Research relationship, Research support Sunovion: Research relationship, Research support Tetraphase: Research relationship, Research support The Medicines Co.: Research relationship, Research support Zoetis: Research relationship, Research support
format Online
Article
Text
id pubmed-5630865
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56308652017-11-07 In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 Walkty, Andrew Adam, Heather J Baxter, Melanie Lagace-Wiens, Philippe Karlowsky, James Hoban, Daryl Zhanel, George Open Forum Infect Dis Abstracts BACKGROUND: Ceftolozane-tazobactam (C/T) is a novel β-lactam β-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of C/T and relevant comparators vs. a large collection of antimicrobial non-susceptible (NS) P. aeruginosa clinical isolates obtained from patients across Canada (CANWARD, 2008–2016). METHODS: From January 2008 to December 2016, inclusive, 12 to 15 sentinel hospitals across Canada submitted clinical isolates from patients attending ERs, medical and surgical wards, hospital clinics, and ICUs (CANWARD). Each center was asked to annually submit clinical isolates (consecutive, one per patient/infection site) from blood, respiratory, urine, and wound infections. Susceptibility testing was performed using broth microdilution as described by CLSI. Multidrug-resistant (MDR) P. aeruginosa were defined as isolates that tested NS to at least one antimicrobial from ≥3 classes. Extensively drug-resistant (XDR) P. aeruginosa were defined as isolates that tested NS to at least one antimicrobial from ≥5 classes. RESULTS: 3229 P. aeruginosa isolates were obtained as a part of CANWARD. The in vitro activity of C/T and relevant comparators is presented below. CONCLUSION: C/T demonstrated excellent in vitro activity vs. antimicrobial NS P. aeruginosa clinical isolates, including MDR, XDR, and meropenem NS subsets. It may prove useful in the treatment of infections caused by these organisms. DISCLOSURES: D. Hoban, Abbott: Research relationship, Research support Achaogen: Research relationship, Research support Astellas: Research relationship, Research support Merck Canada: Research relationship, Research support Merck USA: Research relationship, Research support Paratek Pharma: Research relationship, Research support Pharmascience: Research relationship, Research support Sunovion: Research relationship, Research support Tetraphase: Research relationship, Research support The Medicines Co.: Research relationship, Research support Zoetis: Research relationship, Research support; G. Zhanel, Achaogen: Research relationship, Research support Astellas: Research relationship, Research support Merck Canada: Research relationship, Research support Merck USA: Research relationship, Research support Paratek Pharma: Research relationship, Research support Pharmascience: Research relationship, Research support Sunovion: Research relationship, Research support Tetraphase: Research relationship, Research support The Medicines Co.: Research relationship, Research support Zoetis: Research relationship, Research support Oxford University Press 2017-10-04 /pmc/articles/PMC5630865/ http://dx.doi.org/10.1093/ofid/ofx163.913 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Walkty, Andrew
Adam, Heather J
Baxter, Melanie
Lagace-Wiens, Philippe
Karlowsky, James
Hoban, Daryl
Zhanel, George
In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
title In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
title_full In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
title_fullStr In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
title_full_unstemmed In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
title_short In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
title_sort in vitro activity of ceftolozane-tazobactam vs. antimicrobial non-susceptible pseudomonas aeruginosa clinical isolates obtained from across canada as part of the canward study, 2008–2016
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630865/
http://dx.doi.org/10.1093/ofid/ofx163.913
work_keys_str_mv AT walktyandrew invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016
AT adamheatherj invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016
AT baxtermelanie invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016
AT lagacewiensphilippe invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016
AT karlowskyjames invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016
AT hobandaryl invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016
AT zhanelgeorge invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016